SCHEMBL29313102

SCHEMBL29313102

CCCCCCCCCCCCOc1cc(C)cc(CN)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 0.45
TSHR P16473 1/20 0.45
TP53 P04637 2/20 0.43
ALOX15 P16050 2/20 0.43
NR5A1 Q13285 1/20 0.42
GGPS1 O95749 1/20 0.42
CNR1 P21554 3/20 0.41
CNR2 P34972 2/20 0.41
DHFR P00374 5/20 0.40
BLM P54132 1/20 0.40
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31406505 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL31406517 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL11694989 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL5090331 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL13836862 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL5090437 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL31406472 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL5088868 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL5095048 0.90 PLA2G2A (0.54) PLA2G2ATSHRTP53ALOX15NR5A1
SCHEMBL8641708 0.86 NR5A1 (0.49) PLA2G2ATSHRTP53ALOX15NR5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228433-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS HONGENE BIOTECH CORPORATION 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228433-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS POLR2H, POLRMT, POLR2E PLA2G2A 1952/4885TSHR 2927/4885TP53 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.